Aquestive Therapeutics, Inc. AQST Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 63.5%-4.9pp | 58.3%-10.6pp | 60.3%-9.1pp | 61.1%-7.4pp | 68.4%+8.2pp | |
| Operating margin | -111.2%-35.2pp | -159.5%-106pp | -128.6%-92.7pp | -119.2%-93.2pp | -75.9%-38.2pp | |
| Net margin | -137.1%-37.1pp | -188.1%-111pp | -158.9%-99.2pp | -147.4%-103pp | -100%-44.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×-0.1× | 0.3×-0.4× | 0.3×-0.4× | 0.4×-0.3× | 0.5×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4.1×-0.8× | 3.1×-1.5× | 5.9×-0.4× | 3.5×-4.0× | 4.9×-1.4× | |
| Per Share | ||||||
| Book value per share | -$0.28+56.5% | -$0.31+54.6% | -$0.04+92.5% | -$0.73-87.2% | -$0.64-29.4% | |
| Valuation | ||||||
| Market capitalization | $560.13M+73.5% | $788.14M+143% | $676.24M+49.1% | $318.84M+34.7% | $286.73M-25.2% | |
| Price / sales | 11.1×+5.2× | 17.7×+12.1× | 15.6×+7.9× | 7.2×+3.2× | 5.3×-2.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Aquestive Therapeutics, Inc. (AQST) runs a 63.5% gross margin and a -111.2% operating margin, with a -137.1% net margin.
- Where do Aquestive Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Aquestive Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
